Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study.
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination.
• Age 16 years and above on the day of signing the ICF
• Living with HIV with confirmed test results or clinic records
• History of receiving HPV vaccine
• Self-reported sexually active in the last six months
• Lives within the study area and willing to provide updated locator information over the course of the study
• Does not have an autoimmune, degenerative, or genetic disease
• Does not have known advanced HIV (as per stage IV WHO clinical staging criteria for HIV)
• No other Investigator-determined factor would limit participation in the trial
• Has not and is not enrolled in a monoclonal, investigational vaccine, or a large quantity blood draw study
⁃ The participant has a cervix